A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

This study aims to investigate the efficacy and safety of neoadjuvant therapy with Iparomlimab and Tuvonralimab Injection (anti-PD-1 and anti-CTLA-4 antibody combination) in patients with resectable hepatocellular carcinoma at high risk of recurrence (Stage IB, Stage IIA).

NCT Number	NCT07515469
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection, Neoadjuvant Immunotherapy
Enrollment	30 participants
Start Date	2026-05-30
Primary Completion	2028-05-30 (estimated)
Study Completion	2030-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-07